Navigation Links
Metabasis Therapeutics to Present Poster at American Association,for Cancer Research

SAN DIEGO, March 22, 2007 /PRNewswire-FirstCall/ -- Metabasis Therapeutics, Inc. announced today that a poster entitled, "A Phase I/II Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MB07133 in Subjects with Unresectable Hepatocellular Carcinoma (HCC)" will be presented at the 2007 annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, CA. The presentation will take place on April 16, 2007 from 1:00-5:00 p.m. Pacific Time. The poster will provide data on the safety, tolerability, pharmacokinetics and antitumor activity from a dose escalation clinical trial that the Company recently completed in 28 patients with primary liver cancer.

About Metabasis (www.mbasis.com):

Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving the liver and pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.

CONTACT: Constance Bienfait, Vice President, Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575

Web site: http://www.mbasis.com/

Ticker Sy
'"/>




Page: 1 2

Related medicine technology :

1. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
2. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... According to a May 13, 2013 New Zealand Herald ... Botox injections have become the most popular cosmetic procedure ... goo.gl/8iYbD). Although it is mostly associated with women, Botox ... facial wrinkles less visible by paralyzing facial muscles. The effects ... This means that people who are conscious about their looks ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 ... sports organization, and Bodybuilding.com, the largest online retailer of ... you a new reality-based sports show, Warrior Island. ... vote on; YouTube, Facebook & Twitter, with our unique ... Warrior Island maroons these elite fighters on an island ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... The Las Vegas personal injury law firm Benson, Bertoldo, ... a senior at Coronado High School, is the winner of ... As the winner of the essay contest, Crawford received a ... 1, 2012 and ran through April 30th, 2013. Participating senior ... essay on “The Role of the civil tort system.” The ...
(Date:5/21/2013)... May 21, 2013 While North Carolina ... with comprehensive travel guides. Brunswick Plantation & Golf Resort ... that include access to 27 holes of "Top10" championship ... in North Carolina, knowing the Top 10 ... takes away the overwhelming task of selecting the course ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Recognize Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to ... was recognized for providing important leadership on health care,policy issues ... the 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia ...
... Will Follow 60,000 Women for 5 Years, ... aged 55,years and older have enrolled in a ... of osteoporosis across the globe. Launch of the,Global ... announced,today at ECCEO 8 (Eighth European Congress on ...
... at Tri-City Medical Center (TCMC) achieved union recognition,Wednesday ... Service,confirmed that caregivers strongly supported unionization and had ... TCMC caregivers become members of SEIU United Healthcare ... workers who have achieved industry a,voice on the ...
... month of tough breathing may help asthma sufferers breathe easier ... of Houston professor. , In a move that ... Oath first do no harm Richard Bond, associate ... medical taboo to treat asthma. Although counterintuitive, Bonds studies ...
... under control , , WEDNESDAY, April 9 (HealthDay News) -- In ... swept across eight Midwestern states, but a new study claims ... outbreak was limited, because the number of people in the ... high, explained study co-author Amy A. Parker, from the ...
... Mr. Muneo Takashi has been,named to head ... Organization,(JETRO Chicago). As the new Chief Executive Director, ... completing his assignment in Chicago., As Chief ... in its activities designed to facilitate business development,between ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 3Health News:North County Caregivers Join United Healthcare Workers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Mumps Outbreak in Midwest Could Have Been Worse 2Health News:Mumps Outbreak in Midwest Could Have Been Worse 3Health News:Muneo Takashi Named Chief Executive Director of Japan's Midwest Trade Office 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: